Best Penny Stocks Under $1.00 Right Now

The stock market has had an incredible bull-run since the Great Recession of 2008 and 2009. While stocks are no longer hitting new all-time highs, the price-to-earnings ratios of most S&P 500 companies still look somewhat expensive historically speaking. Many investors are having trouble finding low-priced stocks that have great business fundamentals and actually generate cash flow.

Stocks have gotten expensive both in-terms of share price and their valuation relative to earnings. In more normal markets, a typical S&P 500 company has traded at about fifteen times their earnings. Most stocks are currently trading closer to 20 times their annual earnings. While the stock market is more expensive as a whole than it has been historically, there are still a handful of undervalued stocks that are trading at less than $1.00 per share.

Value investing opportunities do exist if you're looking in the right places. Putting together a list of the best stocks under $1.00 requires investors to look at smaller and riskier companies and in sectors that are either undiscovered or unloved by the market as a whole. Some of these cheap stocks may not look especially attractive today, but long-term investors will profit if they are willing to exercise patience and hold on to shares of these comapnies through multiple economic cycles.

Some of these companies are solid investing ideas because they are too little and considered too risky to attract the interest of most managed mutual funds and Wall Street money managers. Others operate in unloved and untested areas of the market. You may find even find crypto stocks, marijuana stocks, and biotechnology stocks on this list. Others have been beat up by Mr. Market after a long period of slowing profits, but are now actively trying to turn around their business and bounce back. These low-priced stocks operate in a lot of different industries, but these picks all carry two common characteristics. They all have a super-low share price of $1.00 (1 dollar) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.

#1 - Clene

NASDAQ:CLNN

Stock Price:

$0.42 (-$0.02)

P/E Ratio:

-0.91

Market Cap:

$53.64 million

Average Trading Volume:

872,811 shares

Consensus Rating:

Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$7.80 (1,767.4% Upside)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

#2 - Bionomics

NASDAQ:BNOX

Stock Price:

$0.92 (+$0.02)

Market Cap:

$7.49 million

Average Trading Volume:

310,239 shares

Consensus Rating:

Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$9.80 (967.1% Upside)

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

#3 - Integra Resources

NYSEAMERICAN:ITRG

Stock Price:

$0.81 (-$0.04)

P/E Ratio:

-1.26

Market Cap:

$55.51 million

Average Trading Volume:

53,809 shares

Consensus Rating:

Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$4.00 (396.5% Upside)

Integra Resources Corp., a precious metals exploration and development company, engages in the acquisition, exploration, and development of mineral properties in the Great Basin of the Western United States. The company explores for gold and silver deposits. It primarily focuses on developing DeLamar Project located in southwestern Idaho; and the Wildcat and Mountain View Projects located in western Nevada. It also holds a portfolio of early-stage exploration projects in Idaho, Nevada, and Arizona. The company was formerly known as Mag Copper Limited and changed its name to Integra Resources Corp. in August 2017. Integra Resources Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.

#4 - Affimed

NASDAQ:AFMD

Stock Price:

$0.53 (-$0.02)

P/E Ratio:

-0.63

Market Cap:

$79.20 million

Average Trading Volume:

830,964 shares

Consensus Rating:

Moderate Buy (5 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$5.33 (905.7% Upside)

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia. The company also develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. In addition, it has collaboration with Artiva Biotherapeutics to develop the combination of AFM13 with Artiva's AB-101 NK cell therapy; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and research collaboration and license agreement with Genentech for the development and commercialization of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

#5 - Gamida Cell

NASDAQ:GMDA

Stock Price:

$0.38 (+$0.01)

P/E Ratio:

-1.26

Market Cap:

$39.88 million

Average Trading Volume:

3.92 million shares

Consensus Rating:

Moderate Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$5.40 (1,329.7% Upside)

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.

#6 - X4 Pharmaceuticals

NASDAQ:XFOR

Stock Price:

$0.86 (+$0.01)

P/E Ratio:

-1.09

Market Cap:

$144.59 million

Average Trading Volume:

1.22 million shares

Consensus Rating:

Moderate Buy (3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$3.20 (270.2% Upside)

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

#7 - Village Farms International

NASDAQ:VFF

Stock Price:

$0.80 (-$0.02)

P/E Ratio:

-1.28

Market Cap:

$87.64 million

Average Trading Volume:

475,172 shares

Consensus Rating:

Moderate Buy (3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$2.73 (242.8% Upside)

Village Farms International, Inc., together with its subsidiaries, produces, markets, and sells greenhouse-grown tomatoes, bell peppers, and cucumbers in North America. It operates through four segments: Produce, Cannabis-Canada, Cannabis-U.S., and Energy. The company also owns and operates a power plant that generates and sells electricity, and provides thermal heat to British Columbia Hydro and Power Authority; produces and supplies cannabis products to other licensed providers and provincial governments in Canada and internationally; and develops and sells cannabinoid-based health and wellness products, including ingestible, edibles, and topical applications. It markets and distributes its products under the Village Farms brand name to retail supermarkets and fresh food distribution companies, as well as products produced under exclusive arrangements with other greenhouse producers. The company was formerly known as Village Farms Canada Inc. and changed its name to Village Farms International, Inc. in December 2009. Village Farms International, Inc. was founded in 1989 and is headquartered in Delta, Canada.

#8 - ESS Tech

NYSE:GWH

Stock Price:

$0.94 (+$0.03)

P/E Ratio:

-1.68

Market Cap:

$162.94 million

Average Trading Volume:

911,765 shares

Consensus Rating:

Moderate Buy (2 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$3.30 (250.4% Upside)

ESS Tech, Inc., an energy storage company, designs and produces iron flow batteries for commercial and utility-scale energy storage applications worldwide. It offers energy storage products, which include Energy Warehouse, a behind-the-meter solution; and Energy Center, a front-of-the-meter solution. The company was founded in 2011 and is headquartered in Wilsonville, Oregon.

#9 - FTC Solar

NASDAQ:FTCI

Stock Price:

$0.50 (+$0.03)

P/E Ratio:

-0.92

Market Cap:

$62.43 million

Average Trading Volume:

575,789 shares

Consensus Rating:

Moderate Buy (3 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$2.17 (333.9% Upside)

FTC Solar, Inc. provides solar tracker systems, software, and engineering services in the United States and internationally. It offers two-panel in-portrait single-axis tracker solutions under the Voyager brand name. The company also provides Pioneer, a one module-in-portrait solar tracker solution that allows for a pile count reduction per megawatt. Its customers include project developers; solar asset owners; and engineering, procurement, and construction contractors that design and build solar energy projects. FTC Solar, Inc. was incorporated in 2017 and is headquartered in Austin, Texas.

#10 - Outlook Therapeutics

NASDAQ:OTLK

Stock Price:

$0.45 (+$0.03)

P/E Ratio:

-1.87

Market Cap:

$116.75 million

Average Trading Volume:

2.38 million shares

Consensus Rating:

Moderate Buy (5 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$3.37 (650.6% Upside)

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

#11 - Aeva Technologies

NYSE:AEVA

Stock Price:

$0.88 (+$0.04)

P/E Ratio:

-1.31

Market Cap:

$230.23 million

Average Trading Volume:

1.88 million shares

Consensus Rating:

Moderate Buy (3 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$1.62 (83.7% Upside)

Aeva Technologies, Inc. designs 4D LiDAR-on-chips in the United States, Thailand, Europe, the Middle East, and Asia. The company develops its products using frequency modulated continuous wave sensing technology. It offers 4D LiDAR sensing system with embedded software for automotive, industrial, and security applications; and a silicon photonics engine and software algorithms for industrial automation and consumer device applications. The company was founded in 2017 and is based in Mountain View, California.

#12 - Coppernico Metals

OTCMKTS:CPPMF

Stock Price:

$0.02

P/E Ratio:

0.22

Market Cap:

$4.29 million

Average Trading Volume:

19,529 shares

Consensus Rating:

Moderate Buy (3 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$4.25 (21,150.0% Upside)

Copper Mountain Mining Corporation engages in the mining, exploration, and development of mineral properties in Canada. It explores for copper, gold, and silver deposits. The company holds 75% interests in the Copper Mountain mine comprising 135 crown-granted mineral claims, 145 located mineral claims, 14 mining leases, 12 fee simple properties, and seven cell claims that covers an area of approximately 6,354 hectares located to the south of Princeton, British Columbia. Copper Mountain Mining Corporation was incorporated in 2006 and is headquartered in Vancouver, Canada. As of June 20, 2023, Copper Mountain Mining Corporation operates as a subsidiary of Hudbay Minerals Inc.

#13 - Chicken Soup for the Soul Entertainment

NASDAQ:CSSE

Stock Price:

$0.19

P/E Ratio:

-0.01

Market Cap:

$6.09 million

Average Trading Volume:

213,841 shares

Consensus Rating:

Moderate Buy (4 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$4.60 (2,332.6% Upside)

Chicken Soup for the Soul Entertainment, Inc. operates as a streaming video-on-demand (VOD) company in the United States and internationally. It owns and operates various ad-supported and subscription-based VOD networks, including Crackle, Chicken Soup for the Soul, Popcornflix, Popcornflix Kids, Truli, Pivotshare, Popcornflix Comedy, Españolflix, and FrightPix. The company distributes and exhibits content through the Crackle Plus and Redbox streaming services including AVOD, FAST, TVOD platforms, such as connected TVs, smartphones, tablets, gaming consoles, and the web through its owned and operated platforms. It also produces and licenses movies, television series, and programs; and produces long and short-form video content. Chicken Soup for the Soul Entertainment, Inc. was founded in 2014 and is headquartered in Cos Cob, Connecticut. Chicken Soup for the Soul Entertainment, Inc. operates as a subsidiary of Chicken Soup for the Soul Productions, LLC.

#14 - Cara Therapeutics

NASDAQ:CARA

Stock Price:

$0.52 (-$0.01)

P/E Ratio:

-0.24

Market Cap:

$28.34 million

Average Trading Volume:

612,192 shares

Consensus Rating:

Moderate Buy (4 Buy Ratings, 1 Hold Ratings, 1 Sell Ratings)

Consensus Price Target:

$12.79 (2,358.3% Upside)

Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate, including Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. Cara Therapeutics, Inc. has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. and Winhealth Pharma for the co-development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis in China; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. The company was incorporated in 2004 and is based in Stamford, Connecticut.

#15 - Li-Cycle

NYSE:LICY

Stock Price:

$0.40 (+$0.01)

Market Cap:

$71.12 million

Average Trading Volume:

3.22 million shares

Consensus Rating:

Hold (3 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$7.60 (1,804.8% Upside)

Li-Cycle Holdings Corp. engages in the lithium-ion battery resource recovery and lithium-ion battery recycling business in North America. The company offers a mix of cathode and anode battery materials, including lithium, nickel, and cobalt, as well as graphite, copper, and aluminum; and copper and aluminum metals. It also provides hub products, such as lithium carbonate, cobalt sulphate, nickel sulphate, and manganese carbonate. The company is headquartered in Toronto, Canada.

#16 - Galecto

NASDAQ:GLTO

Stock Price:

$0.61 (-$0.01)

P/E Ratio:

-0.34

Market Cap:

$16.54 million

Average Trading Volume:

237,562 shares

Consensus Rating:

Hold (3 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$7.60 (1,145.9% Upside)

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled small molecule inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

#17 - Terran Orbital

NYSE:LLAP

Stock Price:

$0.86 (+$0.05)

P/E Ratio:

-0.91

Market Cap:

$166.59 million

Average Trading Volume:

3.71 million shares

Consensus Rating:

Hold (3 Buy Ratings, 1 Hold Ratings, 1 Sell Ratings)

Consensus Price Target:

$5.45 (536.2% Upside)

Terran Orbital Corporation manufactures and sells satellites for aerospace and defense industry in the United States. It operates through two segments, Satellite Solutions and Earth Observation Solutions. The Satellite Solutions segment offers end-to-end satellite solutions, including spacecraft design, development, launch services, and on-orbit operations for critical missions across a range of applications in various orbits to governmental agencies and commercial businesses. The Earth Observation Solutions segment develops, builds, launches, and operates a constellation of earth observation satellites that has synthetic aperture radar capabilities to provide earth observation data and mission solutions. The company was founded in 2013 and is headquartered in Boca Raton, Florida.

#18 - Rent the Runway

NASDAQ:RENT

Stock Price:

$0.54 (+$0.03)

P/E Ratio:

-0.31

Market Cap:

$37.71 million

Average Trading Volume:

1.18 million shares

Consensus Rating:

Hold (3 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$2.29 (327.7% Upside)

Rent the Runway, Inc. operates shared designer closet in the United States. The company offers evening wear and accessories, ready-to-wear, workwear, denim, casual, maternity, outerwear, blouses, knitwear, loungewear, jewelry, handbags, activewear, and ski wear under subscription, rental, and resale offering. It also engages in the software development and support activities. The company was incorporated in 2009 and is headquartered in Brooklyn, New York.

#19 - NanoString Technologies

NASDAQ:NSTG

Stock Price:

$0.12 (+$0.06)

P/E Ratio:

-0.03

Market Cap:

$5.59 million

Average Trading Volume:

19.77 million shares

Consensus Rating:

Hold (2 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$7.63 (6,462.0% Upside)

NanoString Technologies, Inc. develops, manufactures, and sells technology for scientific and clinical information in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter Pro and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, cartridges, ancillary reagents, tips and reagent plates to setup and process samples in instruments; and Prosigna in vitro diagnostic kits. The company is also developing GeoMx DSP system to enable the field of spatial biology. It has collaboration with Lam Research Corporation for the development of NGS sequencing platform and related assays; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer, as well as collaboration with Stanford Medicine, Acrobat Genomics, and Illumina Accelerator to discover new drug targets for gene editing-based therapeutics. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington.

#20 - Americas Silver

NYSEAMERICAN:USAS

Stock Price:

$0.22

P/E Ratio:

-1.22

Market Cap:

$48.61 million

Average Trading Volume:

418,835 shares

Consensus Rating:

Hold (2 Buy Ratings, 0 Hold Ratings, 1 Sell Ratings)

Consensus Price Target:

$2.07 (838.1% Upside)

Americas Gold and Silver Corporation engages in the acquisition, evaluation, exploration, development, and operation of mineral properties. The company explores for silver, lead, zinc and copper. It principally owns 100% interests in the Cosalá Operations consisting of 67 mining concessions that cover approximately 19,385 hectares located in the state of Sinaloa, Mexico; and Galena Complex situated near the town of Wallace in the state of Idaho, the United States. The company was formerly known as Americas Silver Corporation and changed its name to Americas Gold and Silver Corporation in September 2019. Americas Gold and Silver Corporation was incorporated in 1998 and is headquartered in Toronto, Canada.

#21 - Gossamer Bio

NASDAQ:GOSS

Stock Price:

$0.86 (-$0.01)

P/E Ratio:

-0.49

Market Cap:

$194.08 million

Average Trading Volume:

541,439 shares

Consensus Rating:

Hold (2 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$4.75 (451.7% Upside)

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

#22 - SVB Financial Group

OTCMKTS:SIVPQ

Stock Price:

$0.40 (+$0.02)

P/E Ratio:

0.02

Market Cap:

$23.38 million

Average Trading Volume:

142,184 shares

Consensus Rating:

Hold (4 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings)

Consensus Price Target:

$229.50 (58,001.3% Upside)

SVB Financial Group, a diversified financial services company, offers various banking and financial products and services. It operates through four segments: Silicon Valley Bank, SVB Private, SVB Capital, and SVB Securities. The Silicon Valley Bank segment provides commercial banking products and services, including credit, treasury management, foreign exchange, trade finance, and other financial products and services. This segment also offers traditional term, growth capital term, and equipment loans, asset-based loans, revolving lines of credit, warehouse facilities, recurring revenue and acquisition finance facilities, mezzanine lending, corporate working capital facilities, and credit card programs; treasury management products and services; business and analysis checking, money market, multi-currency, in-country bank, and sweep accounts; receivables services, which include merchant services, remote capture, lockbox, and fraud control services; wire transfer and automated clearing house payment services; business bill pay, credit and debit cards, account analysis, and disbursement services. In addition, it offers foreign exchange and trade finance products and services; letters of credit; and investment services and solutions. The SVB Private segment offers mortgages, home equity lines of credit, restricted and private stock loans, capital call lines of credit, and other secured and unsecured lending products; planning-based financial strategies, wealth management, family office, financial planning, tax planning, and trust services; and real estate secured loans. The SVB Capital segment provides venture capital investment services. The SVB Securities segment provides investment banking services; products and services, including capital raising, merger and acquisition advisory, equity research, and sales and trading. The company was founded in 1983 and is headquartered in Santa Clara, California. On March 17, 2023, SVB Financial Group, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

#23 - Nikola

NASDAQ:NKLA

Stock Price:

$0.71 (+$0.02)

P/E Ratio:

-0.45

Market Cap:

$725.92 million

Average Trading Volume:

93.73 million shares

Consensus Rating:

Hold (2 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$2.83 (299.8% Upside)

Nikola Corporation operates as a technology innovator and integrator that develops energy and transportation solutions. It operates through two business units, Truck and Energy. The Truck business unit develops and commercializes battery electric vehicles (BEV) and hydrogen fuel cell electric vehicles (FCEV) to the trucking sector. The Energy business unit develops and constructs a network of hydrogen fueling stations; and offers BEV charging solutions for its FCEV and BEV customers, as well as other third-party customers. The company also assembles, integrates, and commissions its vehicles in collaboration with its business partners and suppliers. Nikola Corporation founded in 2015 and is headquartered in Phoenix, Arizona.

#24 - Sangamo Therapeutics

NASDAQ:SGMO

Stock Price:

$0.55 (+$0.07)

P/E Ratio:

-0.38

Market Cap:

$97.54 million

Average Trading Volume:

1.45 million shares

Consensus Rating:

Hold (3 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings)

Consensus Price Target:

$4.68 (750.0% Upside)

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.

#25 - Atara Biotherapeutics

NASDAQ:ATRA

Stock Price:

$0.83 (-$0.17)

P/E Ratio:

-0.30

Market Cap:

$84.18 million

Average Trading Volume:

4.45 million shares

Consensus Rating:

Hold (1 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$26.50 (3,108.6% Upside)

Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.

More Stock Ideas from MarketBeat

Get 30 Days of MarketBeat All Access Free

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

• Best-in-Class Portfolio Monitoring

  View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

• Stock Ideas and Recommendations

  Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

• Advanced Stock Screeners and Research Tools

  Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Sign in to your free account to enjoy these benefits

• In-depth profiles and analysis for 20,000 public companies.
• Real-time analyst ratings, insider transactions, earnings data, and more.
• Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

• Sign In
• Create Account

Your Email Address:

Email Address Required

Your Password:

Password Required

---

or

Sign in with Facebook Sign in with Google

Forgot your password?

Your Email Address:

Please enter your email address.

Please enter a valid email address

Choose a Password:

Please enter your password.

Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character.

Create My Account (Free)

---

or

Sign in with Facebook Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.